1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia

Technology appraisal guidance [TA426] Published: 21 December 2016

  • Guidance
  • Tools and resources
  • Information for the public
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 229 KB 23 January 2017  

Final appraisal determination

  • Final appraisal determination  
  • Final appraisal determination document PDF 380 KB 17 November 2016  
  • Committee papers PDF 1.13 MB 17 November 2016  

Invitation to participate

  • Final matrix PDF 96 KB 19 July 2016  
  • Final scope PDF 62 KB 19 July 2016  

Final appraisal determination

  • Final appraisal determination  
  • Final appraisal determination document TA251 PDF 735 KB 15 March 2012  
  • Committee papers TA251 PDF 2.71 MB 15 March 2012  

Draft guidance: TA251

  • Draft guidance: TA251  
  • Committee papers PDF 15.03 MB 10 November 2016  
  • Appraisal consultation document TA251 PDF 669 KB 10 November 2016  

Invitation to participate

  • Final scope TA251 PDF 212 KB 04 February 2011  
  • Final matrix TA251 PDF 66 KB 04 February 2011  
  • Draft scope and provisional matrix comments table (post-referral) TA251 Draft scope comments PDF 387 KB 04 February 2011  
  • Draft scope and provisional matrix comments table (post-referral) TA251 Draft matrix comments PDF 252 KB 04 February 2011